A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC
Status: TERMINATED
Study type: OBSERVATIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Herceptin (trastuzumab)|DRUG: SB3 (proposed trastuzumab biosimilar)
Sponsor: Samsung Bioepis Co., Ltd.